Background: Copeptin, a reliable marker for vasopressin release, has been associated with cardiometabolic diseases including metabolic syndrome (MetS). This systematic review aims to evaluate the association between copeptin and MetS. Methods: We searched in Pubmed, Scopus, EMBASE, and Web of Science databases until March 2021 and included observational studies (cohort studies, cross-sectional, and case-control) reporting the risk or prevalence of having MetS in patients with elevated copeptin levels compared to patients without elevated copeptin levels. Risk of bias was evaluated with the New Castle-Ottawa Scale. Meta-analysis was not performed because of the heterogeneity of the copeptin cut-off values. Results: A total of 7 studies (5 cross-sectional, 1 case-control, 1 cohort) were included comprising 11 699 participants. Most of them were performed in the adult general population. Tw...

We explored the association between serum uric acid (SUA) to metabolic syndrome (MetS) and insulin resistance (IR) among health personnel from a public hospital in Peru in a cross-sectional study with data from the Plan for the Prevention and Surveillance of Communicable and Non-Communicable Diseases of Huaycán Hospital. MetS was defined according to Latin American Diabetes Association (ALAD) criteria and IR with surrogate IR markers, triglycerides to HDL-C ratio (TG/HDL-C), and triglycerides to glucose index (TyG). The association between SUA to MetS and IR was determined using Poisson regression models in a sample of 292 participants with an average age of 46.2 ± 10.6 years. The total prevalence of MetS was 38% and the adjusted regression models showed that women with SUA in the high tertile increased the prevalence of MetS (aRP:1.71, 95%CI: 1.07 – 2.74), hypertriglyceridemia (aRP:...